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Highlights 
 C auris biofilms display decreased sensitivity to skin disinfection agents  
 Candida  species were differentially sensitive to antiseptics 
 Hydrogen peroxide treatment was ineffective against Candida auris biofilms 
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Abstract  
Candida auris has emerged as a significant clinical entity due to its ability to cause 
outbreaks within the healthcare setting. A key feature of its nosocomial lifestyle is its 
ability to transfer between patients, yet little is known about the mechanisms behind this. 
A panel of C. auris clinical isolates was screened for their planktonic and sessile 
susceptibilities to skin disinfection challenge using povidone iodine, chlorhexidine and 
hydrogen peroxide. C. auris biofilms displayed increased tolerance to these strategies 
compared to planktonic cells. Additionally, analysis using a complex biofilm model 
demonstrated reduced susceptibility against clinically relevant concentrations of 
chlorhexidine and hydrogen peroxide, with complete eradication achieved only using 
povidone iodine. Principal component analysis (PCA) also revealed distinct clustering of 
C. auris biofilms in comparison to C. albicans and C. glabrata biofilms, and directionality 
with respect to different treatments. These findings indicate differential responses of 
different Candida species with respect to antiseptic challenge against biofilms, with C. 
auris appearing to be more resilient as a complex community. 
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1. Introduction 
Since its first report in 2009, the emerging multidrug-resistant pathogenic yeast Candida 
auris has attracted considerable attention as a source of healthcare associated 
infections. Alarmingly, it has been attributable for a number of nosocomial outbreaks 
globally, including a UK intensive care unit, whereby almost 20% of colonised patients 
developed candidaemia [1]. High transmission within critical care units has been 
reported, with environmental sampling yielding C. auris from beds and chairs, in addition 
to multiuse patient equipment [2, 3].  The mechanism behind its persistence within the 
healthcare environment is unknown, yet it is thought to be multi-faceted, whereby it 
subsequently contaminates the patient and healthcare environment. The primary site of 
colonisation in patients remains unknown, though it has been isolated from various sites 
of the skin and has also been isolated 3 months after initial identification despite 
antifungal treatment and negative screens [3]. Within the environment, it has been 
shown to survive and persist for prolonged periods on a variety of fomites [4, 5]. 
Disinfection regimens are also problematic, with various studies identifying variable and 
unsatisfactory outcomes [6-8]. Potentially linked to its survival profile is the organisms’ 
ability to exist as a biofilm. Despite biofilm formation initially being dismissed [9], more 
recent studies have demonstrated that C. auris can form highly resistant biofilms [10, 
11]. Several studies have assessed the fungicidal efficacy of antiseptics against 
planktonic C. auris cells [7, 12], however there are minimal data evaluating their 
effectiveness against biofilms. This study used a three-dimensional complex biofilm 
model to investigate the efficacy of a panel of antiseptic therapeutics including povidone 
iodine (PVP-I), chlorhexidine (CHX) and hydrogen peroxide (H2O2). The data presented 
herein, supports the hypothesis that the ability of C. auris to form biofilms may be a 
potential mechanism that results in reduced susceptibility to antiseptic agents. 
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2. Materials and methods 
 
2.1 Strains and culture conditions 
Four C. auris isolates (NCPF 8971, NCPF 8973 [non-aggregative], NCPF 8977, NCPF 
8978 [aggregative]) and C. albicans ATCC 10231 and C. glabrata ATCC 2001 were 
used throughout this study, as previously described [11, 13]. Isolates were stored and 
maintained on Sabouraud dextrose (SAB) agar (Oxoid, Hampshire, UK) prior to 
propagation in yeast peptone dextrose (YPD) (Sigma-Aldrich, Dorset, UK) medium for 
16-18 h, at 30°C with gentle agitation. Cells were then washed by centrifugation in 
phosphate buffered saline ([PBS] Sigma-Aldrich, Dorset, UK), before being standardised 
to assay specific concentrations after counting using the haemocytometer.   
 
2.2 Two-dimensional biofilm formation and susceptibility testing 
For biofilm development, organisms were standardised to 1 × 106 cells/mL in RPMI-
1640 (Sigma-Aldrich, Dorset, UK) and grown at 37°C for 24 and 48 h in 96-well flat-
bottomed microtitre plates (Corning, NY, USA). Following growth, biofilms were washed 
with PBS to remove non-adherent cells and treated with serially two-fold diluted 
concentrations of CHX (1 - 0.002%), PVP-I (10 - 0.02%) and H2O2 (1 - 0.002%). 
Following exposure for 5, 10 and 30 min, the antiseptics were neutralised for 15 min 
using 5% sodium thiosulphate (Fisher Scientific, Loughborough, UK). For both 
planktonic and sessile cells, minimum inhibitory concentrations (MIC), were calculated 
using the XTT [2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2Htetrazolium-5-carboxanilide] 
assay, with the MIC recorded as the concentration which reduced metabolic activity by 
90%, as previously described [14].  
 
2.3 Preparation of hydrogel and biofilm development on cellulose matrix 
Next, the impact of the therapeutics against C. auris NCPF 8971, C. auris NCPF 8978, 
C. albicans and C. glabrata were assessed using a complex wound biofilm model 
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developed in house [15]. Briefly, hydrogels were prepared using 10% 3-sulfopropyl 
acrylate potassium salt, 0.95% poly(ethylene glycol) deacrylate, 0.01% 1-
hydroxycyclohexyl phenyl ketone, with the addition of 50% horse serum (Thermo Fisher 
Scientific, Loughborough, UK) in sterile water to the final volume. Gels were then 
polymerised in 12 well plates (Corning, NY, USA) using a 366nm ultraviolet lamp for 30 
min. For mature biofilm formation, the isolate was standardised to 1 × 107 cells/mL in 
PBS and added to sections of cellulose matrix (1.25 cm2) prior to incubation for 90 min 
at 37°C, with gentle agitation. Sections were then placed on top of the hydrogel and 
incubated for a further 48 h. In addition, early biofilms were grown for 90 min by 
incubating standardised cells on the cellulose matrix, as described above.  
 
2.4 Complex biofilm susceptibility testing 
Following growth in the complex model, biofilms were washed with PBS to remove non-
adherent cells. Biofilms were then challenged with clinically relevant concentrations of 
CHX (0.05%, 2%), PVP-I (10%) and H2O2 (3%) for 5 min, before being neutralised, as 
described above. Following neutralisation, matrices were removed, sonicated at 35 kHz 
for 10 min in an ultrasonic water-bath (Fisher Scientific, Loughborough, UK) to remove 
biofilm cells, with cellular viability determined using the Miles and Misra plate counting 
method [15].  
 
2.5 Scanning Electron Microscopy (SEM) 
Early (90 min) and mature (48 h) biofilms of C. auris NCPF 8971 were grown on 
cellulose matrix as stated above and visualised for SEM as described previously [15]. 
Briefly, biofilms were washed with PBS before fixation using 2% glutaraldehyde, 2% 
paraformaldehyde and 0.15% alcian blue in 0.15M sodium cacodylate and processed for 
SEM. The samples were sputter coated with gold before being visualised using a JEOL 
JSM-6400 scanning electron microscope. 
2.6 Statistics 
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Data distribution, statistical analysis and graph production were performed using 
GraphPad Prism (version 8; La Jolla, CA, USA). Statistics were calculated based from 
log10 reductions from the untreated controls. Data were assessed for normality before 
student t-tests were used to compare treated and untreated samples, with statistical 
significance was achieved if p<0.05. Principle component analysis (PCA) was performed 
on log10 reduction values with R software using in-built functions. Clustering was 
performed using the partitioning around mediods (pam) algorithm using the R package 
‘cluster’. Visualisation by the package ‘ggplot2’ was utliised to provide figures.  
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3. Results 
Initially, the antiseptic efficacy of three agents were tested against four C. auris isolates 
using a 96 well microtitre plate methodology. When biofilms were treated with PVP-I for 
5 min, concentrations of 1.25-2.5% were required to inhibit biofilms, a 16 to 128 fold 
change compared to planktonic cells (Fig 1A). Increasing the exposure time (10 and 30 
min) was shown to increase susceptibility to 0.625-1.25%, 8 to 64 fold change compared 
to planktonic cells. CHX was highly active against planktonic cells, whereas biofilms 
were less susceptible with MIC’s increasing 2 to 16 fold (Fig 1B). Elevated biofilm MIC’s 
were also observed following H2O2 exposure, with concentrations ranging between 0.25 
- >1% required to kill biofilms, i.e. 16-fold increase in the planktonically active 
concentration (Fig 1C). Regardless of the antiseptic active used, minimal differences in 
susceptibility were observed between 24 and 48 h biofilms. Likewise, minimal variation 
was observed between all four C. auris isolates. Strains NCPF 8971 (non-aggregative) 
and NCPF 8978 (aggregative), two phenotypic and genotypically distinct isolates, and 
comparator species C. albicans and C. glabrata were then selected for further 
experimentation using a complex biofilm model. 
Early (90 min) and mature (48 h) biofilms were grown before treatment with clinically 
relevant concentrations of each of the antiseptics. When early biofilms were treated with 
0.05% CHX, mature biofilms demonstrated decreased susceptibility across all tested 
isolates (p<0.001). Both C. auris isolates were less susceptible (<1 log10 reduction), 
compared to 2- and 3- log10 reduction for C. albicans and C. glabrata respectively. When 
the CHX concentration was increased to 2%, complete eradication was shown against 
all early biofilms. This same trend was observed against mature biofilms of C. albicans 
and C. glabrata, however ~103 and ~102 CFU/mL remained viable post treatment for C. 
auris NCPF 8971 (Figure 2A) and NCPF 8978 (Figure 2B) respectively. Visually, CHX 
treated C. auris NCPF 8971 biofilms appeared to fuse and form a coating on the cells 
(Fig 3C, D), with only the top layer of the mature biofilm shown to be covered with CHX 
(Fig 3H, I). The least effective treatment against C. auris was 3% H2O2, with only a ~1-
log10 reduction observed against both C. auris isolates early and mature biofilms (Figure 
2A, B). This treatment was more effective against C. albicans, achieving complete 
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eradication against the early biofilms, however ~102 CFU/mL remained viable for treated 
mature biofilms (p<0.001, Figure 2C). Interestingly, early biofilms of C. glabrata were 
significantly more resilient than mature biofilms against this treatment (p<0.001, Figure 
2D). The most effective treatment strategy was 10% PVP-I, to which regardless of 
Candida isolate or biofilm phase, was able to achieve complete eradication (Figure 2 
A,B,C,D). When analysed visually, residual active agent can be observed encasing the 
treated biofilm cells of C. auris NCPF 8971 (Fig 3B, G). 
The PCA plot (Fig 2E), illustrates clustering of mature biofilms of each of the tested 
isolates and each treatment parameter. Clustering analysis demonstrates two distinct 
clusters between both C. auris isolates (cluster 1) and between C. albicans and C. 
glabrata (cluster 2). Factor loading plots of each treatment demonstrate the contribution 
of the variance on each of the components. The variance between the two clusters is 
seen here to be due to difference to susceptibility between treatments parameters. C. 
albicans and C. glabrata cluster according to susceptibility to H2O2 and CHX 0.05%, both 
of which were ineffective against C. auris. 
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4. Discussion  
Given the multidrug resistant phenotype of C. auris its control within the environment is 
paramount. Its environmental persistence is a key attribute within its pathogenic 
repertoire, and is responsible for a number of outbreaks reported globally [16]. Despite 
being primarily associated with a number of life-threatening, invasive infections including 
wound and bloodstream, it appears also to readily colonise the skin. Additionally, 
person-to-person transmission between close contact individuals of the patient is 
possible, with as little as 4 hours required for the organism to successfully colonise [1]. 
Currently, no known guidelines exist for the successful decolonisation of C. auris. 
Several in vitro investigations have established the susceptibility of the organism to CHX 
[11, 12]; this however has not translated clinically, and patients who are receiving daily 
CHX bathing continued to have C. auris isolated from their skin [1]. Indeed, Moore et al 
(2017) demonstrated formulation dependent sensitivity, with >5 log reductions only 
observed in 2% CHX with the presence 70% isopropyl alcohol [7]. This study however 
investigated suspension testing, therefore the effectiveness of this combination against 
adherent C. auris cells remains unknown. Furthermore, patients can remain colonised 
even following antifungal exposure, with C. auris isolated from skin and urine post-
prolonged echinocandin therapy [17]. Given the propensity of C. auris to form biofilms 
[11], and its isolation from catheter tips [1, 18], skin decolonisation prior to invasive 
therapy could be considerered.  
 
Interestingly, PVP-I, a commonly used pre-surgical wash, was shown to be equally 
active against both early and mature biofilms when assessed by culture. This is in 
agreement with other studies, whereby PVP-I demonstrated excellent fungicidal activity 
against C. auris [7, 12]. The use of 10% PVP-I for surgical skin preparation has been 
used clinically for C. auris, with no reported postoperative infection developed [12]. An 
interesting finding from this study was the ineffectiveness of H2O2 against both 
planktonic and sessile cells of C. auris. These findings differ from those of previous 
studies, whereby H2O2 demonstrated significant fungicidal activity [8, 12]. Discrepancies 
between these findings are likely due to the test methodologies employed, with 
vaporised H2O2 assessed in one of these studies [12].  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 11 
 
Previous studies have identified differential phenotypes of aggregating and non-
aggregating strains of C. auris [11, 13]. Whilst non-aggregating strains are more virulent, 
formation of large aggregates could be thought to complicate disinfection strategies. 
However, based upon the data presented in this and a previous study, this appears not 
to be the case, with minimal differences observed between the two phenotypes. 
Interestingly, our findings highlight potential species variation having regard to H2O2 and 
0.05% CHX susceptibility. Both tested C. auris isolates were shown to be statistically 
more resilient to these treatments compared to C. albicans and C. glabrata. This is 
unlike previous disinfection studies [7, 12], whereby homogenous efficacy was shown 
across all tested Candida species, albeit tested in suspension, suggesting of a C. auris 
biofilm-related tolerance.  
 
This study has its limitations in that we only assessed a small number of Candida 
isolates and that no physical application to disinfection (e.g. wiping) was included, to 
which could influence the survival of C. auris. Future studies assessing the efficacy of 
CHX diluted in alcohol may provide a potential anti-biofilm strategy for successful skin 
disinfection. Collectively these findings illustrate the need for a greater understanding of 
the survival strategies of C. auris. Given the documented high transmissibility between 
patients and the environment, the implementation of stringent infection prevention and 
control procedures, coupled with the biological understanding of the organism will 
ultimately aid the intervention strategies of this emerging pathogen.  
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Figure 1. Fold-change comparisons between biofilm and planktonic MIC values of 
three antiseptics against C. auris. Contact time dependent sessile MICs for PVP-I (A), 
CHX (B) and H2O2  (C). MIC values are presented as the fold-change increase of biofilm 
compared to planktonic MICs, assessed using the XTT assay at a 90% reduction level in 
comparison to untreated control. Error bars represent the standard deviation of the 
means.  
 
Figure 2. Biofilm sensitivities of Candida spp. to antiseptic treatment. Early (90 
min) and mature (48 h) biofilms were treated for 5 min with each antiseptic. Viability 
analysis was performed using the Miles and Misra method for C. auris NCPF 8971 (A), 
C. auris NCPF 8978 (B), C. albicans ATCC 10231 (C) and C. glabrata ATCC 2001 (D). 
Principal component analysis of mature biofilms of each isolate with each treatment 
parameter (E). Data represents triplicate values from 3 independent experiments, with 
statistical analysis between log10 reductions from the positive control of early and mature 
biofilms (* p<0.05, ***p<0.001, ND – not detectable). 
 
Figure 3. Scanning electron micrographs of treated early and mature C. auris 
biofilms. C auris NCPF 8971 biofilms were grown for 90 min (early) and 48 h (mature) 
before being fixed, processed and visualised using SEM. Early biofilms are shown in the 
upper panels A-E, with mature biofilms shown in the lower panels F-J. Treatments are 
indicated as follows: Untreated (A,F), 10% PVP-I (B,G), 0.05% CHX (C,H), 2% CHX 
(D,I) and 3% H2O2 (E,J). Images are view at ×1000 magnification, with ×5000 
magnification (inset).  
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